EIKN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	50.45M	Perf Week	-
Market Cap	-	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf YTD	-
Book/sh	-11.34	P/C	-	EPS next 5Y	-	ROE	-	52W High	- -	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	- -	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	- -	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	-	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	-	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	4.04	EPS Q/Q	-	SMA20	-	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.86	Sales Q/Q	-	SMA50	-	Rel Volume	-	Prev Close	-
Employees	-	LT Debt/Eq	0.82	Earnings	-	SMA200	-	Avg Volume	-	Price	-
IPO	-	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	0	Change	-

Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level, supporting targeted treatment development. The company's approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Eikon Therapeutics Inc

Upgrade your FINVIZ experience